key: cord-0071738-get74fia
authors: Xanthouli, Panagiota
title: Eosinopenie als Biomarker des Schweregrads einer COVID-19-Infektion
date: 2021-11-23
journal: nan
DOI: 10.1159/000520808
sha: 5a3f5288647971ee0f8977e6f9bc39e98aa896a0
doc_id: 71738
cord_uid: get74fia

BACKGROUND: Studies on the role of eosinophils in coronavirus disease 2019 (COVID-19) are scarce, though available findings suggest a possible association with disease severity. Our study analyzes the relationship between eosinophils and COVID-19, with a focus on disease severity and patients with underlying chronic respiratory diseases. METHODS: We performed a retrospective analysis of 3018 subjects attended at two public hospitals in Madrid (Spain) with PCR-confirmed SARS-CoV-2 infection from January 31 to April 17, 2020. Patients with eosinophil counts less than 0.02×10(9)/L were considered to have eosinopenia. Individuals with chronic respiratory diseases (n = 384) were classified according to their particular underlying condition, i.e., asthma, chronic pulmonary obstructive disease, or obstructive sleep apnea. RESULTS: Of the 3018 patients enrolled, 479 were excluded because of lack of information at the time of admission. Of 2539 subjects assessed, 1396 patients presented an eosinophil count performed on admission, revealing eosinopenia in 376 cases (26.93%). Eosinopenia on admission was associated with a higher risk of intensive care unit (ICU) or respiratory intensive care unit (RICU) admission (OR:2.21; 95%CI:1.42–3.45; p <0.001) but no increased risk of mortality (p >0.05). CONCLUSION: Eosinopenia on admission conferred a higher risk of severe disease (requiring ICU/RICU care), but was not associated with increased mortality. In patients with chronic respiratory diseases who develop COVID-19, age seems to be the main risk factor for progression to severe disease or death.

lying condition, i.e., asthma, chronic pulmonary obstructive disease, or obstructive sleep apnea. Results: Of the 3018 patients enrolled, 479 were excluded because of lack of information at the time of admission. Of 2539 subjects assessed, 1396 patients presented an eosinophil count performed on admission, revealing eosinopenia in 376 cases (26.93%). Eosinopenia on admission was associated with a higher risk of intensive care unit (ICU) or respiratory intensive care unit (RICU) admission (OR:2.21; 95%CI: 1.42-3.45; p < 0.001) but no increased risk of mortality (p > 0.05). Conclusion: Eosinopenia on admission conferred a higher risk of severe disease (requiring ICU/RICU care), but was not associated with increased mortality. In patients with chronic respiratory diseases who develop COVID-19, age seems to be the main risk factor for progression to severe disease or death. 

Biomarker für die Früherkennung des Schwergrads einer COVID-19-Infektion sind mangelhaft [1] . Die Bestimmung der Akut-Phase-Proteine (C-reaktives Protein (CRP), D-Dimere, Ferritin, Procalcitonin u.a.) ist teuer, zeitaufwendig und häufig ungenau [1] , was das Gesundheitssystem zunehmend finanziell belastet. Die Bestimmung von Eosinophilen und der Nachweis und die Persistenz der Eosinopenie (Mangel von Eosinophilen) deuten einen komplizierten Verlauf [2] der COVID-19-Infektion an [3] . Weitere Studien über die Funktion der Eosinophilen während der COVID-19-Infektion sind erforderlich. 

Risk factors for severe and critically ill CO-VID-19 patients: A review

Eosinopenia

Eosinophil responses during CO-VID-19 Infections and coronavirus vaccination